Bariatric surgery review positions GLP-1 drugs as adjunct, not substitute
Incretins achieve roughly 15% to 21% total body weight loss but require sustained dosing, versus 25% to 35% with metabolic and bariatric surgery.
MH
By Maren Holt · Senior Reporter, GLP-1
The wire
- 01A narrative review in Surgery for Obesity and Related Diseases synthesizes evidence that GLP-1-based therapies produce about 15% to 21% total body weight loss in randomized trials while metabolic and bariatric surgery typically achieves 25% to 35% with durable metabolic benefit.
- 02Authors argue framing the two as competing risks delaying definitive intervention, and propose bariatric programs act as the multidisciplinary medical home coordinating pharmacologic, endoscopic and surgical care.
- 03Gaps remain on optimal timing, patient selection, duration of therapy and cost-effectiveness of combined strategies; this is a narrative review rather than comparative trial data.
From the source
Read at pubmed.ncbi.nlm.nih.govGLP-1 receptor agonists and bariatric surgery: complement, not competition: An integrated framework for contemporary obesity management: a narrative review
Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery · 2026 Aug 4 · Chumakova-Orin M, Juo Y, Fanelli R et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42823265/
